Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6656783 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1PTGS2NPC1RAB9A | |
| SCHEMBL600722 | 0.85 | LMNA (0.52) | — | |
| SCHEMBL600723 | 0.85 | LMNA (0.52) | — | |
| SCHEMBL9301856 | 0.82 | APEX1 (0.53) | CNR1NPC1RAB9A | |
| SCHEMBL2489081 | 0.82 | APEX1 (0.53) | CNR1NPC1RAB9A | |
| SCHEMBL39941 | 0.82 | APEX1 (0.53) | CNR1NPC1RAB9A | |
| SCHEMBL2490383 | 0.80 | ALOX5 (0.54) | CNR1NPC1RAB9A | |
| SCHEMBL6367852 | 0.79 | ALOX5 (0.58) | NPC1RAB9A | |
| SCHEMBL6654014 | 0.77 | GSK3B (0.51) | ALDH1A1NPC1RAB9A | |
| SCHEMBL6654010 | 0.77 | GSK3B (0.51) | ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254241-A1 | Enzyme inhibitor; cognition activators | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1431280-A1 | ARYL SULFAMATE DERIVATIVES | Kyowa Hakko Kogyo Co., Ltd (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254241-A1 | Enzyme inhibitor; cognition activators | SULT1A1, STS, CYP26A1 | ALDH1A1 1187/4885CNR1 322/4885PTGS2 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.